NEPHROCARE HEALTH SERV L Intrinsic Value
NEPHROPLUS · Healthcare · Current price ₹692.2
Is NEPHROCARE HEALTH SERV L undervalued?
DocStoX estimates the fair value of NEPHROCARE HEALTH SERV L at ₹337 per share, versus the current market price of ₹692. That puts the stock about -51.4% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹107), Relative P/E (₹519), Graham floor (₹138), Analyst target (₹835). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹107 (bear) to ₹337 (base) to ₹835 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Margin of safety
Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹692 versus an intrinsic value of ₹337, NEPHROCARE HEALTH SERV L currently offers -51.4% of negative margin (i.e. a premium).
More on NEPHROCARE HEALTH SERV L
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.